A Phase 3 study performed in a higher number (n=132) of patients with gMG, including both AChR- and MuSK-positive patients (101), showed batoclimab ability to significantly increase the rate of sustained MG-ADL improvement, as early as week 2 for 4 or more consecutive weeks, with clinical effects and IgG reduction being similar to those previously reported for efgartigimod and rozanolixizumab. The gene discussed is MUSK; the disease is myasthenia gravis.